Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov. Counted 2026-11-10.
Most participants first33,758 with no events in either group come last661 to 680 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Hydrochlorothiazide vs Chlorthalidone: Proportion of Participants Had Nonfatal Stroke | 83 of 6,767 83 of 6,756 | -0.0 points -0.4 to 0.4 | 13,523 | NCT02185417 Diuretic Comparison Project |
| Hydrochlorothiazide vs Chlorthalidone: Proportion of Participants Had Hospitalization for Heart Failure | 232 of 6,767 242 of 6,756 | -0.2 points -0.8 to 0.5 | 13,523 | NCT02185417 Diuretic Comparison Project |
| Hydrochlorothiazide vs Chlorthalidone: Proportion of Participants Had Unstable Angina Leading to Urgent Coronary Revascularization | 13 of 6,767 20 of 6,756 | -0.1 points -0.3 to 0.1 | 13,523 | NCT02185417 Diuretic Comparison Project |
| Hydrochlorothiazide vs Chlorthalidone: Proportion of Participants Deceased and Not Related to Cancer | 354 of 6,767 359 of 6,756 | -0.1 points -0.8 to 0.7 | 13,523 | NCT02185417 Diuretic Comparison Project |
| Hydrochlorothiazide vs Chlorthalidone: Proportion of Participants Had Nonfatal Myocardial Infarction | 140 of 6,767 142 of 6,756 | -0.0 points -0.5 to 0.5 | 13,523 | NCT02185417 Diuretic Comparison Project |
| Hydrochlorothiazide vs Chlorthalidone: deaths from any cause | 448 of 6,767 446 of 6,756 | 0.0 points -0.8 to 0.9 | 13,523 | NCT02185417 Diuretic Comparison Project |
| Hydrochlorothiazide vs Chlorthalidone: serious adverse events | 1,977 of 6,767 1,990 of 6,756 | -0.2 points -1.8 to 1.3 | 13,523 | NCT02185417 Diuretic Comparison Project |
| Prasugrel vs Clopidogrel: serious adverse events | 1,731 of 6,741 1,675 of 6,716 | 0.7 points -0.7 to 2.2 | 13,457 | NCT00097591 A Comparison of Prasugrel (CS-747) and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention |
| TICAGRELOR vs CLOPIDOGREL: Participants With Any Event From the Composite of Death From Vascular Causes, MI, and Stroke for the Subgroup of Patients With Intent for Invasive Management at Randomization | 569 of 6,732 668 of 6,676 | -1.6 points -2.5 to -0.6 | 13,408 | NCT00391872 A Comparison of Ticagrelor (AZD6140) and Clopidogrel in Patients With Acute Coronary Syndrome |
| With Dyslipidaemia vs Without Dyslipidaemia: Number of Participants With Treatment-Related Adverse Events: With/Without Complication (Dyslipidaemia) | 99 of 5,308 109 of 8,035 | 0.5 points 0.1 to 1.0 | 13,343 | NCT01252563 Amlodipine 10mg Drug Use Investigation |
| With Complication(s) vs Without Complication(s): Number of Participants With Treatment-Related Adverse Events: With/Without Complication(s) | 170 of 9,177 38 of 4,166 | 0.9 points 0.5 to 1.3 | 13,343 | NCT01252563 Amlodipine 10mg Drug Use Investigation |
| With ARB vs Without ARB: Number of Participants With Treatment-Related Adverse Events: With/Without Concomitant Drug (ARB) | 118 of 6,641 90 of 6,702 | 0.4 points 0.0 to 0.9 | 13,343 | NCT01252563 Amlodipine 10mg Drug Use Investigation |
| Male vs Female: Number of Participants With Treatment-Related Adverse Events: Male vs. Female | 87 of 7,504 121 of 5,839 | -0.9 points -1.4 to -0.5 | 13,343 | NCT01252563 Amlodipine 10mg Drug Use Investigation |
| With Angina Pectoris vs Without Angina Pectoris: Number of Participants With Treatment-Related Adverse Events: With/Without Complication (Angina Pectoris) | 21 of 872 187 of 12,471 | 0.9 points 0.0 to 2.2 | 13,343 | NCT01252563 Amlodipine 10mg Drug Use Investigation |
| With Antihypertensive vs Without Antihypertensive: Number of Participants With Treatment-Related Adverse Events: With/Without Concomitant Drug (Antihypertensive) | 136 of 7,834 72 of 5,509 | 0.4 points 0.0 to 0.8 | 13,343 | NCT01252563 Amlodipine 10mg Drug Use Investigation |
| Part B (Blinded): mRNA-1273 at Month 6 vs Part B (Blinded): mRNA-1273.222 at Month 6: Part B: Number of Participants With Serious Adverse Events (SAEs) | 212 of 11,243 45 of 2,012 | -0.4 points -1.1 to 0.3 | 13,255 | NCT05168813 Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern |
| Part B (Blinded): mRNA-1273 at Month 6 vs Part B (Blinded): mRNA-1273.222 at Month 6: Part B: Number of Participants With Adverse Events of Special Interest (AESIs) | 111 of 11,243 27 of 2,012 | -0.4 points -1.0 to 0.1 | 13,255 | NCT05168813 Efficacy Study of COVID-19 mRNA Vaccine in Regions With SARS-CoV-2 Variants of Concern |
| Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With Composite of Stroke/MI/Death | 442 of 6,589 497 of 6,610 | -0.8 points -1.7 to 0.1 | 13,199 | NCT01994720 [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] |
| Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With Ischaemic Stroke | 385 of 6,589 441 of 6,610 | -0.8 points -1.7 to -0.0 | 13,199 | NCT01994720 [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] |
| Ticagrelor 90 mg vs ASA 100 mg: Number of Participants With CV Death | 41 of 6,589 35 of 6,610 | 0.1 points -0.2 to 0.4 | 13,199 | NCT01994720 [SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES] |
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=34
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT02185417-61970e8e",
"title": "Hydrochlorothiazide vs Chlorthalidone: Proportion of Participants Had Nonfatal Stroke",
"summary": "83 of 6767 against 83 of 6756; risk difference -0.0 points, 95% interval -0.4 to 0.4; NCT02185417, Diuretic Comparison Project",
"record": "/library/comparisons/NCT02185417-61970e8e",
"nct_id": "NCT02185417",
"kind": "outcome",
"participants": 13523,
"risk_difference": {
"value": -0.000019970317065638732,
"lower": -0.0037723881504740323,
"upper": 0.003731200726633902
},
"group_1": "83 of 6,767",
"group_2": "83 of 6,756",
"difference": "-0.0 points",
"interval": "-0.4 to 0.4",
"trial_title": "Diuretic Comparison Project"
},
{
"id": "NCT02185417-acddd0d7",
"title": "Hydrochlorothiazide vs Chlorthalidone: Proportion of Participants Had Hospitalization for Heart Failure",
"summary": "232 of 6767 against 242 of 6756; risk difference -0.2 points, 95% interval -0.8 to 0.5; NCT02185417, Diuretic Comparison Project",
"record": "/library/comparisons/NCT02185417-acddd0d7",
"nct_id": "NCT02185417",
"kind": "outcome",
"participants": 13523,
"risk_difference": {
"value": -0.0015359864238591106,
"lower": -0.007759840347928783,
"upper": 0.004680352091816752
},
"group_1": "232 of 6,767",
"group_2": "242 of 6,756",
"difference": "-0.2 points",
"interval": "-0.8 to 0.5",
"trial_title": "Diuretic Comparison Project"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "None stated"
}
],
"next": "/api/comparisons/v1?page=35",
"request_id": "MeQvXP8-u-4vWEBv"
}ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
For invited accounts.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant